Insulet Corporation

Insulet Corporation, headquartered in Acton, Massachusetts, is a global medical device manufacturer specializing in insulin delivery systems. The company is the maker of Omnipod, a line of tubeless, wearable, Pod-based insulin management systems designed to eliminate multiple daily injections for people with diabetes. Omnipod systems provide continuous insulin delivery through waterproof (IP28 rated), connected pods with integrated glucose monitoring and automated insulin delivery capabilities. The Omnipod 5 system is the #1 U.S. requested and prescribed Automated Insulin Dosing (AID) system as of 2025. Insulet serves over 600,000 global customers across 25 countries, with 2025 revenue of $2.7 billion. The company maintains manufacturing and office facilities worldwide and operates with a focus on regulatory compliance and innovation in diabetes management. Insulet is publicly traded on NASDAQ under ticker PODD and demonstrates commitment to sustainability and responsible growth. The company's product development is driven by extensive research and development focused on simplifying diabetes management for patients. Omnipod devices feature tubeless design, waterproofing for practical daily use, and integration with continuous glucose monitoring systems.